Astrana Health (NASDAQ:ASTH) Coverage Initiated by Analysts at Needham & Company LLC

Needham & Company LLC started coverage on shares of Astrana Health (NASDAQ:ASTH) in a research note released on Friday morning, MarketBeat Ratings reports. The brokerage issued a buy rating and a $28.00 price objective on the stock.

ASTH has been the subject of several other research reports. Zacks Research cut shares of Astrana Health from a “hold” rating to a “strong sell” rating in a report on Monday, November 10th. Barclays reduced their price objective on Astrana Health from $36.00 to $26.00 and set an “equal weight” rating for the company in a research note on Monday, November 24th. Weiss Ratings reissued a “sell (d+)” rating on shares of Astrana Health in a report on Monday. Jefferies Financial Group reaffirmed a “buy” rating on shares of Astrana Health in a report on Tuesday, November 25th. Finally, TD Cowen decreased their price target on Astrana Health from $40.00 to $35.00 and set a “buy” rating for the company in a report on Monday, November 10th. Eight investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Astrana Health has an average rating of “Moderate Buy” and an average target price of $41.33.

Astrana Health Price Performance

NASDAQ ASTH opened at $23.47 on Friday. The stock’s fifty day moving average price is $26.99 and its 200 day moving average price is $26.76. Astrana Health has a 1 year low of $20.12 and a 1 year high of $39.97. The company has a debt-to-equity ratio of 1.27, a current ratio of 1.40 and a quick ratio of 1.40. The company has a market cap of $1.32 billion, a price-to-earnings ratio of 123.53, a PEG ratio of 1.35 and a beta of 0.86.

Astrana Health (NASDAQ:ASTH) last announced its quarterly earnings data on Wednesday, January 10th. The company reported $0.50 earnings per share for the quarter. Astrana Health had a return on equity of 1.26% and a net margin of 0.33%.The business had revenue of $317.00 million for the quarter. As a group, equities research analysts forecast that Astrana Health will post 1.15 earnings per share for the current year.

Institutional Trading of Astrana Health

Several institutional investors have recently bought and sold shares of the business. Ameriprise Financial Inc. raised its stake in shares of Astrana Health by 231.0% during the 3rd quarter. Ameriprise Financial Inc. now owns 442,314 shares of the company’s stock worth $12,540,000 after buying an additional 308,665 shares during the period. 325 Capital LLC raised its position in Astrana Health by 34.6% during the third quarter. 325 Capital LLC now owns 1,193,953 shares of the company’s stock worth $33,849,000 after acquiring an additional 307,037 shares during the period. Vanguard Group Inc. lifted its holdings in Astrana Health by 4.5% during the first quarter. Vanguard Group Inc. now owns 4,898,992 shares of the company’s stock valued at $151,918,000 after purchasing an additional 213,033 shares in the last quarter. Pacer Advisors Inc. purchased a new position in Astrana Health during the third quarter valued at $5,157,000. Finally, Hotchkis & Wiley Capital Management LLC acquired a new stake in shares of Astrana Health in the first quarter valued at about $5,564,000. 52.77% of the stock is owned by institutional investors and hedge funds.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.